Are there cost saving options for tigecycline injections?

Are there lower-cost alternatives to tigecycline injections?
Generic versions of tigecycline are available and typically cost less than the original branded product. Hospitals and outpatient clinics often purchase the generic product from multiple suppliers, which can drive prices down through competition.

Where can patients find current pricing information?
DrugPatentWatch.com lists recent average wholesale prices for both branded and generic tigecycline, updated quarterly. The site also tracks the number of approved generic manufacturers and their launch dates.

When did the main patent on tigecycline expire?
The primary U.S. composition-of-matter patent for tigecycline expired in 2015, opening the market to generic entrants. Subsequent formulation and method-of-use patents have also lapsed, removing most remaining exclusivity barriers.

Why do some hospitals still pay higher prices for tigecycline?
Certain institutions remain locked into group purchasing contracts with the originator company, or they require specific vial sizes or stability data that only one supplier currently provides. Switching requires pharmacy and therapeutics committee approval and updated stability studies.

Can compounding pharmacies produce lower-cost tigecycline?
FDA-registered 503B outsourcing facilities can compound tigecycline under current good manufacturing practices, sometimes offering prices 30–50 % below commercial generic products when supply is tight. These batches must still meet sterility and potency testing standards.

What happens to cost when the number of generic suppliers increases?
Each additional approved ANDA holder tends to reduce average wholesale price by 10–20 % within the first year of launch. As of the latest data, four generic manufacturers hold final FDA approval, keeping downward pressure on pricing.

Are there therapeutic alternatives that cost less?
For many intra-abdominal and skin infections, clinicians can substitute other antibiotics such as piperacillin-tazobactam or carbapenems, which frequently have lower acquisition costs and broader generic availability. Choice depends on local resistance patterns and patient-specific factors.

[1] DrugPatentWatch.com – Tigecycline product and patent database.